Aflibercept is a recombinant fusion protein that binds to vascular endothelial growth factor (VEGF) receptors 1 and 2. By binding to these receptors, it inhibits the action of both VEGF-A and placental growth factor, thus reducing the abnormal growth of blood vessels that is associated with wet AMD.1
Investigators randomised patients (n=2,419) in a 1:1:1:1 ratio to receive the following treatments by intravitreal injection: aflibercept 500 microgram monthly; aflibercept 2mg monthly; aflibercept 2mg monthly for 3 months then every two months; or ranibizumab 500 microgram monthly.2
The primary endpoint was maintenance of vision, defined as losing fewer than 15 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart.2
Non-inferior to ranibizumab
At week 52, all aflibercept groups in both trials met the 7% non-inferiority margin when compared with monthly ranibizumab for the primary endpoint in a pre-specified integrated analysis. Additionally, the aflibercept groups were within 0.5 letters of the ranibizumab group in terms of mean change in best corrected visual acuity in the combined analysis.2
Safety and tolerability
The safety profile of aflibercept was comparable to that of ranibizumab, with similar rates of both ocular and non-ocular adverse events.2
- Eylea Summary of Product Characteristics, November 2012.2. Heier JS et al. Ophthalmology 2012; 119; 2537–48.
- Heier JS et al. Ophthalmology 2012; 119; 2537–48.
Further information: Bayer plc